myelodysplastic syndrome Mar 11, 2021 Whole-Genome Sequencing Could Replace Cytogenetics in Assessing AML, Myelodysplastic Syndromes Dec 29, 2020 Aprea's Eprenetapopt Fails to Meet Primary Endpoint in Phase III Trial of TP53-Mutant MDS Nov 24, 2020 Clinicians Face New Intervention Questions as Clonal Hematopoiesis Mutation Data Evolves Premium Nov 12, 2020 Jubilant Therapeutics, OneThree Biotech ID Biomarkers for LSD1, HDAC6 Inhibitor Oct 7, 2020 Aprea Therapeutics to Begin Phase I Trial for APR-548 in Myelodysplastic Syndromes Oct 2, 2020 Mustang Bio Initiates Cell Therapy Trial in Patients With CD123-Positive Blood Cancers Sep 18, 2020 MSK Clonal Hematopoiesis Clinic Aims to Drive New Strategies for Cancer Risk Assessment, Prevention Premium Aug 14, 2020 MDS Patients Fare Worse With Two Mutated Copies of TP53 Than One, Research Shows Premium Jul 15, 2020 Notable's Drug Sensitivity Assay IDs Rx for Blood Cancer Patients When NGS Can't, Small Study Shows Premium Jun 19, 2020 Aprea's Drug for TP53-Mutant Cancers Moves Into Registrational Trials for Myelodysplastic Syndromes Premium Aug 12, 2019 Mission Bio, Onconova Therapeutics Sign Cancer Therapy Research Partnership Jul 17, 2019 Cancer Drug Discovery Firm Notable Nabs $40M in Series B Funding Round Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
